BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 14, 2004
View Archived Issues
TKT Says It Will No Longer Seek U.S. Replagal Approval
Transkaryotic Therapies Inc. lost 23.5 percent of its stock value after announcing its decision to abandon efforts to win U.S. approval of Replagal, an enzyme replacement therapy for Fabry's disease. (BioWorld Today)
Read More
Curis Inks $170M Deal To License Hedgehog Technology To Wyeth
Read More
Synta's Beefy Pipeline Gets $50M In Series C Financing
Read More
BioStratum Could Receive $80M Per Antibody In Novo Cancer Deal
Read More
Neurogen's C5a Antagonist Fails Phase IIa Asthma Trial
Read More
Acumen, Merck Sign Alzheimer's Disease Pact With $96M Potential
Read More
Other News To Note
Read More